N,N,N-Trimethyl-3-[(4-methylbenzene-1-sulfonyl)oxy]propan-1-aminium | 64845-73-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N,N-Trimethyl-3-[(4-methylbenzene-1-sulfonyl)oxy]propan-1-aminium
• 英文别名: trimethyl-[3-(4-methylphenyl)sulfonyloxypropyl]azanium
• CAS: 64845-73-4
• 化学式: C13H22NO3S+
• 分子量: 272.39
• InChiKey: RESIYOYTSRXCJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'ADMINISTRER DES AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2017099823A1

  公开（公告）日：2017-06-15

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

  这项披露提供了改进的基于脂质的组合物，包括脂质纳米粒子组合物，以及它们用于体内传递药剂的方法，包括核酸和蛋白质。这些组合物不受加速血清清除的影响，并且它们在体内具有改进的毒性特性。
• Compositions and methods for delivery of agents
  申请人：ModernaTX, Inc.

  公开号：US10207010B2

  公开（公告）日：2019-02-19

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

  本公开提供了改进的脂基组合物（包括脂质纳米颗粒组合物）及其使用方法，用于在体内递送包括核酸和蛋白质在内的制剂。这些组合物不会加速血液清除，而且在体内具有更好的毒性特征。
• COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
  申请人：ModernaTX, Inc.

  公开号：EP3386484A1

  公开（公告）日：2018-10-17
• COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS
  申请人：ModernaTX, Inc.

  公开号：US20180028664A1

  公开（公告）日：2018-02-01

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.